DrugPatentWatch Database Preview
Drugs in Development Information for Defactinib
Email this page to a colleague
See Plans and PricingWhat is the development status for investigational drug Defactinib?
Defactinib is an investigational drug.
There have been 14 clinical trials for Defactinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Mesothelioma, Ovarian Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Verastem, Inc., Merck Sharp & Dohme Corp., and NHS Greater Glasgow and Clyde.
There are five US patents protecting this investigational drug and forty-three international patents.
Summary for Defactinib
| US Patents | 5 |
| International Patents | 43 |
| US Patent Applications | 16 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2013-09-01) |
| Vendors | 46 |
Recent Clinical Trials for Defactinib
| Title | Sponsor | Phase |
|---|---|---|
| Pembrolizumab + Defactinib In Pleural Mesothelioma | Merck Sharp & Dohme Corp. | Phase 1 |
| Pembrolizumab + Defactinib In Pleural Mesothelioma | Raphael Bueno, MD | Phase 1 |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Merck Sharp & Dohme Corp. | Phase 2 |
Clinical Trial Summary for Defactinib
Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib
US Patents for Defactinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Defactinib | Start Trial | Methods and compositions for treating abnormal cell growth | Verastem, Inc. (Needham, MA) | Start Trial |
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer Inc (New York, NY) | Start Trial |
| Defactinib | Start Trial | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer Inc (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Defactinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Defactinib | European Patent Office | 3102232 | 2034-02-07 | Start Trial |
| Defactinib | Hong Kong | 1232152 | 2034-02-07 | Start Trial |
| Defactinib | Japan | 2017505321 | 2034-02-07 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
